Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI) to discover the next generation of small molecule medicines,announced the appointment of Adrian Schreyer, Ph.D., as Chief Technology Officer.
Read More : Schneider Electric Launches Digitally Enabled SureSeT Medium Voltage Switchgear in Canada
“I am thrilled to welcome Adrian to Anagenex. His groundbreaking AI enabled drug discovery experience will drive our platform capabilities to new heights as we work to further enhance our integrated AI and lab capabilities,” said Nicolas Tilmans, CEO of Anagenex. “We look forward to seeing what Adrian will build, armed with our multi billion compound small molecule datasets and ability to build 100 million compound target focused libraries.”
“Anagenex’s unique ability to build molecules at speed and multi-modal selection strategies create the kind of high quality data essential to drive AI and identify molecules to solve challenging biology,” said Adrian Schreyer, Ph.D., CTO of Anagenex. “I am excited to join this team of experienced scientists and engineers to continue the platform’s development and unlock its full potential to find medicines faster.”
Adrian Schreyer is a pioneering leader in AI powered drug discovery with extensive experience in drug development. Prior to joining Anagenex, he spent over a decade at Exscientia where he was a founding member of the team and went on to support the company through a successful IPO while building its AI team from scratch and eventually serving as the company’s Chief Technology Officer. The AI enabled drug discovery engine he designed during his time at Exscientia is one of the only AI platforms to drive compounds from discovery into the clinic. Adrian holds a B.Sc. in Applied Biology from the Bonn-Rhein-Sieg University of Applied Sciences and a Ph.D. in Structural Bioinformatics and Drug Discovery from the University of Cambridge.
Read More : Mapping Nvidia’s Expansion with 17 Strategic Acquisitions
Adrian joins the team following the company’s recent announcement of a multi-target collaboration with Nimbus Therapeutics to discover small molecule d**** for multiple challenging targets, underscoring Anagenex’s continued momentum.
Read More : Top 50 CIO Influence Interviews: Insights from Industry Leaders
[To share your insights with us as part of editorial or sponsored content, please write to sghosh@martechseries.com]
